Introduction {#s1}
============

Safety concerns about tacrolimus include neurological adverse events (NAEs) similar to other calcineurin inhibitors \[[@SFS067C1]--[@SFS067C4]\]. In a 1991 prospective study (*n* = 44), NAEs were reported in 32% of liver transplant recipients on tacrolimus \[[@SFS067C5]\]. In 2007, a large prospective study (*n* = 1645) reported NAEs to be present in 10--15% of patients treated with calcineurin inhibitors for 1 year \[[@SFS067C6]\]. We report here a kidney transplant recipient who developed a life-threatening demyelinating sensorimotor polyneuropathy while on tacrolimus.

Case report {#s2}
===========

A 59-year-old African-born female patient underwent renal deceased donor heterotopic transplantation in August 2000. Cytomegalovirus serology was negative in the donor, positive in the recipient; Epstein-Barr virus serology was positive in both donor and recipient. Initial immunosuppression consisted of basiliximab 20 mg at days 0 and 4, then cyclosporine (targeted plasma level 150--200 µg/L), azathioprine (1--2 mg/kg/day) and steroids. At day 7, cyclosporine was switched to tacrolimus (targeted plasma level 8--10 µg/L) because of digestive intolerance. Two episodes of mild rejection at months (M) 4 and 106 were successfully treated.

Otherwise, creatinine and tacrolimus serum levels remained stable over many years ([Fig. 1](#SFS067F1){ref-type="fig"}). Fig. 1.Tacrolimus whole blood levels (cross symbols) and clinical findings over time following transplantation. 0 = graft; M = month post-graft; D = days after 1st neurological manifestations; IVIGs=intravenous immunoglobulins. Overall disability sum score (filled circles) was retrospectively calculated according to Merkies ISJ *et al.*, J Neurol Neurosurg Psychiatry, 2002. Tacrolimus whole blood levels were quantified by means of an immunoassay. (**A**) Variations of tacrolimus levels from M17 to M117 (full line = mean level, dotted lines = highest and lowest levels ever measured). (**B**) Onset of neurological manifestations at M118 = D0. (**C**) First neurological impairment at D94. (**D**) Switch from tacrolimus to sirolimus and beginning of IVIGs at D105. (**E**) First clinical improvement at D106.

Ten years after the graft, at M118, the patient complained about painful paresthesias first in both hands, and 1 month later in her feet. At M120, neurological examination revealed distal loss of touch and vibratory sensations of four extremities. The sensory nerve action potentials (SNAPs) were absent in the ulnar, median and sural nerves ([Tables 1](#SFS067TB1){ref-type="table"} and [2](#SFS067TB2){ref-type="table"}). At M121, the patient was hospitalized for stance and gait disorders. General examination was normal, tendon reflexes were preserved, but all sensory modalities were reduced in her distal upper and lower limbs. On the fourth hospital day, tacrolimus serum level was found to be elevated at 22.2 µg/L. The patient was found to have been erroneously receiving a double dose since admission. This was corrected and 5 days later, the tacrolimus level had almost normalized at 13.2 µg/L, but the neurological manifestations worsened. A repeat nerve conduction study demonstrated findings consistent with motor neuronal demyelination and absent SNAPs ([Table 1](#SFS067TB1){ref-type="table"}). The patient also developed hypertension, tachycardia, profuse sweating, alternating diarrhea--constipation, urinary incontinence, multiple electrolyte disorders consistent with dysautonomia and delirium related to severe hyponatremia (117 mmol/L, normal range 135--145 mmol/L) and opiate toxicity. Results of extensive laboratory and radiology studies were all negative. Two days later, intravenous infusions of immunoglobulins (IVIGs) were started (2 g/kg over 4 days), and tacrolimus was switched to sirolimus. With further supportive treatment, all symptoms improved rapidly over the next 3 weeks, and the patient was discharged home after a 2-month hospital stay (M123). Two months later (M125), she was independent in all activities of daily living; however, diffuse hyporeflexia, bilateral hypoesthesia in a stocking and glove distribution with distal reduction of vibration sense, with some gait and Romberg unsteadiness, were still present. Table 1.Results of nerve conduction studies (right side unless otherwise mentioned) at months 2.5 (A), 4 (B) and 7 (C) after the onset of neurological manifestations^a^NerveRecording siteParametersABCNormalMotor studiesMedianAbductor pollicis brevisDistal latency (ms)4.517.4\<4.0Amplitude (mV)6.80.2\>5Duration (ms)1037.8\<6CV (m/s)520\>50TibialAbductor hallucisDistal latency (ms)NR0\<6.5Amplitude (mV)\>3PeronealExtensor digitorum brevis (Tibialis anterior)Distal latency (ms)7.50(6)12\<6.0 (\<2.0)Amplitude (mV)0.4(0.1)0.4\>3 (\>4)Duration (ms)(15)15\<6 (\<8)F-wave latency (ms)0\<52Sensory studiesMedian (digit 2)WristAmplitude (μV)0NR\>7SuralAnkle (right and left)Amplitude (μV)000\>5[^1] Table 2.Main characteristics of the 12 reported cases of tacrolimus-induced neuropathy (references in text)^a^ReferencesSex, age in yearsType of graftTacrolimus treatment detailsSymptoms onset (time after transplant)Clinical signsType of conduction abnormalitiesTreatmentOutcomeAyres *et al*. \[[@SFS067C8]\]Male, 31Livertacrolimus 0.3 mg/kg daily from day 7 after transplantD8Flaccid quadriparesis; Renal failureMotor axonalComplete resolution within a few daysComplete recoveryAyres *et al*. \[[@SFS067C8]\]Male, 58Liverpo from D7 on, 0.3 mg/kg/dD8Flaccid quadriparesisMotor, axonalTacrolimus withdrawalComplete recoveryWilson *et al*. \[[@SFS067C15]\]Male, 57 (diabetes mellitus)LiverNone givenShortly afterParesthesias, and foot drops over 6 monthsMultifocal, demyelinatingPLEX over 10 daysImprovement over monthsWilson *et al*. \[[@SFS067C15]\]Male, 60LiverNone givenD14Distal paresthesias, walking difficulties over 2 monthsMultifocal, demyelinatingPLEX over 10 days, and IVIGsImprovement over monthsWilson *et al*. \[[@SFS067C15]\]Male, 35 (alcoholic cirrhosis)LiverNone givenD14Distal paresthesias with weakness, bedriddenSensori-motor, axonalIVIGs over 3 daysImprovement over 3 weeks, then lost to follow-upBronster *et al*. \[[@SFS067C11]\]Male, 45LiverComplex (see reference)Over the 4 months following transplantDisabling distal paresthesiasGeneralized, demyelinatingTacrolimus switched to cyclosporineImprovement over weeksLaham *et al*. \[[@SFS067C14]\]Male, 40KidneyComplex (see reference)D14Distal muscle weaknessMultifocal, demyelinatingWithdrawal of tacrolimus; IVIGs over 5 daysRecovery within 19 weeksBoukriche *et al*. \[[@SFS067C10]\]Male, 52LungTacrolimus plasma level elevatedD3Distal paresthesias, weakness and inability to walkSensori-motor, axonalTransient cessation of tacrolimusImprovement over monthsBhagavati *et al*. \[[@SFS067C9]\]Female, 44Kidney3 mg bid10 monthsFacial twitching and numbness, gait dysbalanceDemyelinating, involving limbs and cranial nervesIVIGs over 5 daysImprovement over months, recovery after 3 monthsBhagavati *et al*. \[[@SFS067C9]\]Male, 53Kidney12 mg, then 7 mg bidImmediatelyNone givenDiffuse, predominantly axonal neuropathyTacrolimus dose reduced to 2 mg bidResolution after 5--6 weeksDe Weerdt *et al*. \[[@SFS067C12]\]Female, 44Liver and pancreasTacrolimus 0.04-0.08 mg/kgD9Distal muscle weaknessAsymmetric motor axonalTacrolimus dose reduced, IVIGs over 5 daysImprovement over months (walking aids after 2 years)Labate *et al*. \[[@SFS067C13]\]Female, 56HeartTacrolimus 5 mg bid2 monthsProgressive paresthesias in the lower limbsSymmetric, sensorimotor demyelinatingTacrolimus switched to cyclosporineImprovement over months[^2]

Discussion {#s3}
==========

Ten years after the graft, this 59-year-old kidney transplant recipient experienced a life-threatening sensorimotor peripheral neuropathy strongly suggesting a diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). A tacrolimus-induced adverse event has been judged probable (score of 5/13 according to the Naranjo Adverse Drug Reaction Probability Scale) \[[@SFS067C7]\].

We identified 12 other published reports of tacrolimus-related polyneuropathy \[[@SFS067C8]--[@SFS067C15]\]. The onset was within the first 3 months after initiation of tacrolimus in most of the patients, but one presented with symptoms after 10 months of treatment. Tacrolimus blood levels were described as over the target range in five cases. Demyelinating type of neuropathy was predominant. In contrast, tacrolimus has been used as an immunosuppressant treatment in two cases of primary CIDP \[[@SFS067C16], [@SFS067C17]\].

The underlying mechanism in our patient is probably inflammatory and non-toxic, given the fast and excellent response to the single course of IVIGs. The cause of inflammation is undetermined and some undiagnosed infection remains a possibility. Autoimmune damage is another possibility, a tacrolimus-triggered event in the context of dysimmunity in this graft recipient being possible.

In summary, our case contributes quite unique features of what is already known on tacrolimus-induced neuropathy:

1\. The adverse effect occurred 10 years after initiation of tacrolimus.

2\. A causal role of tacrolimus is suggested by a suggestive temporal relationship, long-term response after cessation of treatment, exclusion of other causes, some degree of dose--response relationship during transient overdosage and consistency with previously published cases.

3\. Tacrolimus could be switched safely to sirolimus. Sirolimus-induced neurotoxicity has rarely been described \[[@SFS067C18], [@SFS067C19]\]. In our patient, it has been well tolerated so far after an ongoing treatment of 18 months.

In conclusion, this case illustrates that a drug-induced adverse reaction may occur a long time after starting tacrolimus. Early discontinuation of the offending drug and immunomodulation by IVIGs are the key components of management given the potential for a life-threatening course.
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[^1]: ^a^Data are all abnormal, characterized by prolonged distal motor latencies and desynchronization of the motor responses, and absence of sensory responses, suggestive of sensorimotor demyelinating neuropathy---ms, milliseconds; μV or mV, micro or millivolts; m/s, metre/second; CV, conduction velocity; NR, not recorded; 0, absent.

[^2]: ^a^D, days post-graft; iv, intravenous; IVIGs, intravenous immunoglobulins.
